

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79139

Title: Successful Treatment of Patients With Refractory Idiopathic Membranous Nephropathy With Low-dose Rituximab: A Single-Center Experience

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03567482

Position: Peer Reviewer

Academic degree: MD, PhD

Professional title: Assistant Professor

Reviewer's Country/Territory: South Korea

Author's Country/Territory: China

Manuscript submission date: 2022-09-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-09 08:38

Reviewer performed review: 2022-09-28 11:03

Review time: 19 Days and 2 Hours

| | |
|--------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |

| | |
|-------------------------------------|---|
| Peer-reviewer statements | Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No |
|-------------------------------------|---|

SPECIFIC COMMENTS TO AUTHORS

This is an interesting retrospective study of successful treatment of patients with refractory PLA2R-associated membranous nephropathy with low-dose rituximab. This study is over all very well designed, and the results are interesting. Comments: 1. The abstract should be re-written as background, aim, methods, results, and conclusion. 2. Some minor language polishing should be corrected. 3. Limit of the study should be discussed. 4. A conclusion section should be added to the main text. 5. The references list should be edited and updated.

PEER-REVIEW REPORT

Name of journal: *World Journal of Clinical Cases*

Manuscript NO: 79139

Title: Successful Treatment of Patients With Refractory Idiopathic Membranous Nephropathy With Low-dose Rituximab: A Single-Center Experience

Provenance and peer review: Unsolicited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05238726

Position: Peer Reviewer

Academic degree: MD

Professional title: Associate Professor

Reviewer's Country/Territory: China

Author's Country/Territory: China

Manuscript submission date: 2022-09-06

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-09-09 08:39

Reviewer performed review: 2022-09-28 11:03

Review time: 19 Days and 2 Hours

| | |
|--------------------|---|
| Scientific quality | <input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish |
| Language quality | <input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection |
| Conclusion | <input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection |
| Re-review | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |

| | |
|-------------------------------------|---|
| Peer-reviewer statements | Peer-Review: [<input checked="" type="radio"/>] Anonymous [<input type="radio"/>] Onymous Conflicts-of-Interest: [<input type="radio"/>] Yes [<input checked="" type="radio"/>] No |
|-------------------------------------|---|

SPECIFIC COMMENTS TO AUTHORS

In this study, the authors conducted a retrospective study on nine patients with refractory phospholipase A2 receptor-associated MN to explore the efficacy and safety of a new low-dose RTX regimen. The authors found that the titers of anti-PLA2R decreased after administering low-dose RTX, and four patients had a normal anti-PLA2R titer at six months. The level of CD19+ B cells decreased to 0 at three months, and the count of CD19+ B cells lasted to 0 until six months of follow-up. The results are interesting and well discussed. The reviewer recommends to accept this manuscript after a minor editing. Thank you.